Transfusion triggers in acute coronary syndromes: The MINT trial

Similar documents
Blood transfusions in ICU: double-edged sword. Paul Hébert, MD MHSc(Epid) Physician-in-Chief, CHUM Professor, University of Montreal

Patient Blood Management: Enough is Enough

Transfusion & Mortality. Philippe Van der Linden MD, PhD

Transfusion Indications: Update in 2019

Transfusion for the sickest ICU patients: Are there unanswered questions?

Controversies in Transfusion Medicine

Blood Transfusion Project. Reducing Transfusion in the MARCQI Population

Liberale versus restriktive EK-Transfusion

Clinical Controversies in Perioperative Medicine

Red Cell Transfusion triggers: A moving target When, who, and how much?

Clinical Controversies in Perioperative Medicine!

Blood Product Utilization A Mythbusters! Style Review. Amanda Haynes, DO 4/28/18

HIP ATTACK Trial: Can we improve outcomes after a hip fracture with accelerated surgery? PJ Devereaux, MD, PhD

Patient Blood Management Are you providing this? Jeannie Callum, BA, MD, FRCPC Associate Professor, University of Toronto

EVIDENCE BASED RED CELL TRANSFUSION. Rana Samuel, MD DIRECTOR, PATHOLOGY AND LABORATORY MEDICINE VA WNY Health Care System

HB TRIGGER & SINGLE UNITS

Transfusions in Acute Care Too Little?

Blood Pressure Treatment Goals

Red blood cell transfusions in the PICU: What & When

Year in Review: Critical Care Medicine

CCS Perioperative Guidelines When to order a BNP and What to do with a Positive Troponin

Austrian Society for Blood Transfusion and Regenerative Medicine. Klagenfurt - May 2015

Blood transfusions in sepsis, the elderly and patients with TBI

SESSION 5 2:20 3:35 pm

Patient characteristics Intervention Comparison Length of followup

Science Evidence Cost

A Systematic Review and Meta-Analysis of Pre-Transfusion Hemoglobin Thresholds for Allogeneic Red Blood Cell Transfusions

Advances in Transfusion and Blood Conservation

Guidelines PATHOLOGY: FATAL PERIOPERATIVE MI NON-PMI N = 25 PMI N = 42. Prominent Dutch Cardiovascular Researcher Fired for Scientific Misconduct

Transfusion Medicine Potpourri. BUMC - Phoenix Internal Medicine Residents September 29, 2015

Blood Management 2016

Morris A. Blajchman, MD, FRCP(C) Emeritus Professor, McMaster University Hamilton, Ontario, CANADA

efs.sante.fr The best blood donor and blood product for each patient: an evolving role for haemovigilance? Pierre Tiberghien Etablissement Français du

Do PPIs Reduce Bleeding in ICU? Revisiting Stress Ulcer Prophylaxis. Deborah Cook

Cardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology

Transfusion Pitfalls. Objectives. Packed Red Blood Cells. TRICC trial (subgroups): Is transfusion always good? Components

Clinical Controversies in Perioperative Medicine

JOURNAL CLUB INDICATIONS FOR AND ADVERSE EFFECTS OF RED CELL TRANSFUSION. Maggie Woods PGY-3

Faculty/Presenter Disclosure

Should All Patients Be Treated with Ace-inh /ARB after STEMI with Preserved LV Function?

Restrictive & Liberal Red Cell Transfusion Strategies in Adult Patients Reconciling Clinical Data with Best Practice

Goal Directed Therapy : Liberal vs Restrictive Transfusion.. Syafri Kamsul Arif

Top HF Trials to Impact Your Practice

Drug induced hemolysis: transfusion management Interactive case study

TACO Est ce que cette complication transfusionnelle peut être prédite et prévenue?

Effective Date: Approved by: Laboratory Director, Jerry Barker (electronic signature)

Predicting Short Term Morbidity following Revision Hip and Knee Arthroplasty

Catheter-based mitral valve repair MitraClip System

How we View & Approach TACO

Smoking Cessation Interventions In Hospital Settings: Implementing the Evidence

Vasopressors in Septic Shock. Keith R. Walley, MD St. Paul s Hospital University of British Columbia Vancouver, Canada

Objectives. Current WHO Definition of Anemia. Implication for Clinical Practice 10/8/18. Prevalence of Iron Deficiency in Women Undergoing Surgery

Fluid Management in Critically Ill AKI Patients

Preoperative Cardiac Evaluation:

Red blood cell transfusions Risks, benefits, and surprises

APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES

Session Antiplatelet Therapy: How, Why and When? In patients with ischemic stroke/tia

On-Pump vs. Off-Pump CABG: The Controversy Continues. Miguel Sousa Uva Immediate Past President European Association for Cardiothoracic Surgery

4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?

Transfusion Requirements and Management in Trauma RACHEL JACK

Pneumonia and Cardiac Disease

The importance of follow-up after a cardiac event: CARDIAC REHABILITATION. Dr. Guy Letcher

ERYTHROPOIETIC STIMULATING AGENTS IN THE ICU: A MOVING PUZZLE

Peri-Operative Management: Guidelines for Inpatient Management of Children with Sickle Cell Disease

Carotid Artery Stenosis

Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials

Myocardial Infarction In Dr.Yahya Kiwan

Conventional vs. Goal Directed Perfusion (GDP) Management: Decision Making & Challenges

The Clinical Unmet need in the patient with Diabetes and ACS

Dr Tushar Mahambrey. Consu ltant Critical Care Med icine & Anaesthetics St Helens and Knowsley N H S teaching hospitals Liverpool

Assessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington

Timing of Vasopressors in Septic Shock: How Soon is Too Soon?

ACS-NSQIP 2015 Julietta Chang MD, Ali Aminian MD, Stacy A Brethauer MD, Philip R Schauer MD Bariatric and Metabolic Institute

Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.

Patient Blood Management: At the Forefront of Quality and Value in Healthcare

Value of cardiac rehabilitation Prof. Dr. L Vanhees

Supplementary Online Content

Do Elderly Men Have Increased Mortality Following Hip Fracture?

DECLARATION OF CONFLICT OF INTEREST. None declared

Coronary Revascularization for Severe LV Dysfunction Is s. Is the concept of viability testing still viable?

No conflicts of interest to disclose

Heme (Bleeding and Coagulopathies) in the ICU

Evaluating Clinical Risk and Guiding management with SPECT Imaging

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Perioperative Stroke for the General Anesthesiologist and Specialist

Perioperative Myocardial Infarction

Approach to Multi Vessel disease with STEMI

COMPARISON OF EXISTING ANEMIA GUIDELINES WORLDWIDE. R Vanholder, University Hospital, Gent, Belgium

Does Transfusion Practice in Prairie Mountain Health Meet AABB Guidelines?

Overview of session. Blood transfusions in advanced disease 3/21/18. Why am I interested in blood transfusions?

Use of Acute Kidney Injury Biomarkers in Clinical Trials

Use of Acute Kidney Injury Biomarkers in Clinical Trials

High Intensity Interval Exercise Training in Cardiac Rehabilitation


Relations of Interest

ICSS Safety Results NOT for PUBLICATION. June 2009 ICSS ICSS ICSS ICSS. International Carotid Stenting Study: Main Inclusion Criteria

Blood Pressure Targets in Diabetes

NEWS ON ISCHEMIC HEART DISEASE AT THE ESC 2018 CONGRESS MARIO MARZILLI, MD, PhD

A nationwide population-based study. Pai-Feng Hsu M.D. Shao-Yuan Chuang PhD

Cindy L. Grines MD FACC FSCAI

Transcription:

Transfusion triggers in acute coronary syndromes: The MINT trial Paul Hébert, MD MHSc(Epid) Physician-in-Chief, CHUM Professor, University of Montreal

Objectives Review evidence on transfusion triggers Describe upcoming studies on transfusion triggers No relevant competing interests

Purpose: Are a restrictive and liberal red cell transfusion strategy are equivalent in terms of effects on mortality and morbidity in critically ill patients Hebert et al. NEJM 321: 151-156, 1999

Study Design Study design: Multicentre RCT Setting: 25 ICUs across Canada Study Population: Included Hb< 90 g/l within 72 hrs and excluded patients with active blood loss (30 g/l decrease or >3 unit transfusion in 12 hrs) Intervention: 70 g/l vs 100 g/l hemoglobin trigger Outcomes: 30 day all-cause mortality and organ failure Hebert et al. NEJM 321: 151-156, 1999

Survival (%) Survival of all patients over 30 days 100 90 Restrictive strategy 18.7% 80 70 Liberal strategy 23.3% 60 p=0.10 50 0 5 10 15 20 25 30 Time (Days) Hebert et al. NEJM 321: 151-156, 1999

Complications Complication Liberal Restrictive P Values (n=420) (n=418) Cardiac No. (%) 88 (21.0) 55 (13.2) <0.01 Myocardial Infarction 12 (2.9) 3 (0.7) 0.02 Pulmonary Edema 45 (10.7) 22 (5.3) <0.01 Angina 9 (2.1) 5 (1.2) 0.28 Cardiac Arrest 33 (7.9) 29 (6.9) 0.6 Pulmonary No. (%) 122 (29.1) 106 (25.4) 0.22 ARDS 48 (11.4) 32 (7.7) 0.06 Pneumonia 86 (20.5) 87 (20.8) 0.92

Survival (%) Survival (%) Cardiovascular Disease Patients with cardiovascular diseases (n=357) Patients with ischemic heart disease (n=257) 100 100 90 Liberal Restric tiv e 90 Liberal Restric tiv e 80 80 70 70 60 p = 0.95 60 p = 0.30 50 0 5 10 15 20 25 30 Time (Days) 50 0 5 10 15 20 25 30 Time (Days) Hebert et al. NEJM 321: 151-156, 1999

30-Day Mortality Carson JL, Stanworth, Hebert, et al. Cochrane Database of Systematic Reviews 2016

NEJM editorial title

Odds Ratio Effect of anemia on mortality in cardiac disease 16 13 10 7 Healthy (No IHD) Ischemic Heart Disease P=0.03 Retrospective cohort of patients who refuse blood transfusion CVD definition - History of MI, angina, CHF, or PVD. 1,958 patients age 18 or older. Undergo surgical procedure in OR. Outcome-30-day mortality or morbidity. 4 1 6 7 8 9 10 11 12+ Preoperative Hgb (g/dl) Carson JL, et al. Lancet 1996;348:1055-60.

Hebert and Fergusson,JAMA, 2004 How do Rao and Wu studies compare? Both studies document harm from RBC transfusion with hematocrits exceeding 33% Reasons for differences at hematocrits< 33% Different population (younger and aggressively treated in Rao study) Different data acquisition Primary data collection vs administrative database Different statistical techniques Different event rates

Functional outcomes in cardiovascular patients undergoing surgical hip fracture repair (FOCUS) Design: Multicentre RCT in 47 North American centres Study Population: 2016 hip fracture patients undergoing surgical repair with a Hb < 100 g/l within 3 days fo surgery Intervention: Liberal Strategy: transfusion trigger of 100 g/l Restrictive Strategy: transfusion for symptomatic anemia Outcomes: Primary: functional recovery (ability to walk 10 feet without human assistance 60 days post-op) Long term survival, nursing home placement, post-op complications (MI and infection) Carson et al. NEJM 2011, pp2453-62.

Hospital Outcomes Carson JL et al. N Engl J Med 2011;365:2453-2462

Transfusion Threshold Trials in Acute MI 144 patients enrolled in two small trials 9 deaths in 78 patients in Restrictive Group 2 deaths in 76 patients in Liberal Group Risk ratio=3.88 (95% CI, 0.83 to 18.13)

MINT Pilot Trial Clinical Outcomes at 30 Days Death/MI/ Revascularization Liberal N=55 Restrictive N=54 6 (10.9%) 14 (25.9%) Death 1 (1.8%) 7 (13.0%) MI 5 (9.1%) 7 (13.0%) Revascularization 0 (0.0%) 2 (3.7%) Absolute risk difference (95% CI) 15.0% (0.7 to 29.3)* 11.2%** (1.5 to 20.8) 13.0% (-7.9 to15.6) 3.7% (-1.3 to 8.7) *p=0.054, adjusted for age p=0.076 **p=0.032 Carson et al Am Heart Journal 2013

CRIT Trial Clinical Outcomes at 30 Days Liberal N=21 Restrictive N=24 P value Death, recurrent MI, CHF 13 (61.9%) 5 (20.1%) 0.046 Death 1 (4.7%) 2 (8.3%) NS CHF 8 (38.1%) 2 (8.3%) 0.03 Cooper et al Am Heart Journal 2013

Restrictive Liberal

Murphy et al, NEJM 2015

Published on-line October 12, 2016

2016 AABB Transfusion Guidelines Restrictive transfusion 7 to 8 g/dl in most patients No recommendation made in acute coronary syndrome where the evidence is judged to be insufficient for any recommendation Need trials in patients with acute MI

Myocardial Ischemia and Transfusion Trial Design: Multicentre RCT in 70 North American centres Study Population: 3500 patients with either ST or nonst MI (consistent with 3rd Universal definition) with Hb < 100 g/l Intervention: Liberal Strategy: transfusion trigger of 100 g/l Restrictive Strategy: transfusion permitted if hemoglobin concentration falls below 80 g/l and strongly recommended below 70 g/l. transfusion for symptomatic anemia Outcomes: All cause mortality and non-fatal re-infarction within 30 days

Take home messages In most ICU patients, a threshold of 70 g/l should be the new normal In cardiac surgery, await results of TRICS III In acute coronary syndrome, unknown but 80 g/l seems reasonable Join the MINT trial

Thank you